Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>

In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and...

Full description

Bibliographic Details
Main Authors: María del Mar Álvarez-Torres, Elies Fuster-García, Carmen Balaña, Josep Puig, Juan M. García-Gómez
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
glioblastoma
<i>MGMT</i> methylation
tumor vascularity
chemotherapy
adjuvant temozolomide
temozolomide cycles
Online Access:https://www.mdpi.com/2072-6694/13/21/5420

Internet

https://www.mdpi.com/2072-6694/13/21/5420

Similar Items